Rob Hershberg, HilleVax CEO
One of Tachi's newly born legacy biotechs raises $135M and enlists an A-list board to advance late-stage vaccine
Tachi is gone, but his legacy biotechs are continuing to make news.
This morning it’s the newly born HilleVax — a creation of Takeda and Frazier …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
